Crescent Biopharma Inc. Common Stock (CBIO)
Stock · NASDAQ · Health Care
$17.75as of 8/28/2026
Price chart
Open in TradingViewActive signals
About CBIO
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commerciali…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 69
- Website
- www.crescentbiopharma.com/
Fundamentals
- 1-day range
- $17.02$18
- Market cap
- $552.33M
- P/E (trailing)
- —
- P/E (forward)
- -6.75
- EPS (trailing)
- $-7.41
- Dividend yield
- —
- Beta
- 1.29
- Avg. volume
- 318.1K
How Crescent Biopharma Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
5 analyst ratings
Crescent Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CBIOCrescent Biopharma Inc. Common Stock$17.74▼ 0.14%Market cap $552.33MP/E —$8.72$27.41
- MPLTMapLight Therapeutics Inc. Common Stock$12.64▲ 0.80%Market cap $569.09MP/E —$9.1$40.43
- ARVNArvinas Inc. Common Stock$9.16▼ 0.87%Market cap $520.04MP/E 62.96$6.97$14.51
- CRMDCorMedix Inc. Common Stock$8.31▼ 0.06%Market cap $592.31MP/E 3.53$6.13$14.96
- QTTBQ32 Bio Inc. Common Stock$15.01▼ 7.06%Market cap $451.37MP/E 15.71$1.62$23.57
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$8.74▼ 4.79%Market cap $660.88MP/E —$7$14.87
- SGMTSagimet Biosciences Inc. Series A Common Stock$10.55▼ 1.86%Market cap $441.53MP/E —$4.5$11.15
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CBIO Crescent Biopharma Inc. Common Stock | $552.33M | — | $17.74 | ▼ 0.14% | $8.72$27.41 |
| MPLT MapLight Therapeutics Inc. Common Stock | $569.09M | — | $12.64 | ▲ 0.80% | $9.1$40.43 |
| ARVN Arvinas Inc. Common Stock | $520.04M | 62.96 | $9.16 | ▼ 0.87% | $6.97$14.51 |
| CRMD CorMedix Inc. Common Stock | $592.31M | 3.53 | $8.31 | ▼ 0.06% | $6.13$14.96 |
| QTTB Q32 Bio Inc. Common Stock | $451.37M | 15.71 | $15.01 | ▼ 7.06% | $1.62$23.57 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $660.88M | — | $8.74 | ▼ 4.79% | $7$14.87 |
| SGMT Sagimet Biosciences Inc. Series A Common Stock | $441.53M | — | $10.55 | ▼ 1.86% | $4.5$11.15 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Targetbenzinga · 8/27/2026
- Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price TargetBenzinga · 8/27/2026
Insider Activity
Insider Actions →- Fairmount Funds Management LLC · July 16, 2026 · Buy525.9K @ $14.5
- Fairmount Funds Management LLC · July 16, 2026 · Buy853.5K @ $14.5
- Jan Pinkas · June 22, 2026 · Sale1.3K @ $17.99
- Ryan Lynch · June 22, 2026 · Sale465 @ $17.99
- Richard William Scalzo · June 22, 2026 · Sale1.1K @ $17.99
- Barbara Harlin Bispham · June 22, 2026 · Sale1.2K @ $17.99
- Ellie Eunkyung Im · June 22, 2026 · Sale1.2K @ $17.99
- Jonathan McNeill · June 22, 2026 · Sale20.5K @ $17.99
- Joshua T. Brumm · June 22, 2026 · Sale42.3K @ $17.99
- Violin Jonathan · June 2, 2026 · Grant11.1K
- David Charles Lubner · June 2, 2026 · Grant11.1K
- Balcom Alexandra · June 2, 2026 · Grant11.1K
- Susan Moran · June 2, 2026 · Grant11.1K
- Fairmount Healthcare Fund II L.P. · June 2, 2026 · Grant11.1K
See the full, filterable feed with live charts on the MarketWall dashboard.